Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG weekly Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E26.29 EPS (ttm)3.14 Insider Own9.30% Shs Outstand2.29B Perf Week-2.04%
Market Cap205.26B Forward P/E13.22 EPS next Y6.24 Insider Trans0.05% Shs Float2.26B Perf Month-4.24%
Income7.21B PEG3.68 EPS next Q1.43 Inst Own10.90% Short Float0.09% Perf Quarter-3.19%
Sales49.53B P/S4.14 EPS this Y-43.60% Inst Trans-0.49% Short Ratio1.15 Perf Half Y-16.08%
Book/sh23.51 P/B3.51 EPS next Y9.23% ROA6.00% Target Price101.00 Perf Year-9.52%
Cash/sh2.53 P/C32.62 EPS next 5Y7.15% ROE13.60% 52W Range69.18 - 99.84 Perf YTD-12.95%
Dividend3.09 P/FCF32.52 EPS past 5Y-6.50% ROI8.60% 52W High-17.44% Beta0.48
Dividend %3.75% Quick Ratio0.60 Sales past 5Y-1.90% Gross Margin71.00% 52W Low19.15% ATR1.22
Employees110000 Current Ratio0.80 Sales Q/Q-3.30% Oper. Margin18.70% RSI (14)39.09 Volatility1.02% 1.32%
OptionableYes Debt/Eq0.65 EPS Q/Q-10.30% Profit Margin14.60% Rel Volume0.94 Prev Close82.43
ShortableYes LT Debt/Eq0.48 EarningsJul 21 BMO Payout89.50% Avg Volume1.74M Price82.43
Recom1.00 SMA20-2.73% SMA50-4.60% SMA200-6.56% Volume0 Change0.00%
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Aug-11-20 10:41AM  
Aug-07-20 11:30AM  
Aug-06-20 01:42PM  
08:13AM  
07:57AM  
Aug-05-20 05:01PM  
Aug-04-20 04:11PM  
11:38AM  
08:18AM  
01:15AM  
Aug-03-20 04:07PM  
11:54AM  
Aug-02-20 04:31PM  
Jul-31-20 03:41AM  
Jul-30-20 06:43PM  
Jul-28-20 11:40AM  
09:26AM  
Jul-27-20 03:18PM  
01:24PM  
Jul-24-20 02:06PM  
10:27AM  
Jul-22-20 09:34AM  
04:01AM  
Jul-21-20 04:22PM  
12:40PM  
12:23PM  
11:54AM  
09:54AM  
09:39AM  
09:00AM  
07:58AM  
05:16AM  
04:00AM  
01:30AM  
01:29AM  
01:00AM  
Jul-16-20 08:31AM  
07:28AM  
01:24AM  
01:15AM  
Jul-15-20 10:05PM  
09:00AM  
07:21AM  
Jul-14-20 06:42PM  
05:03PM  
Jul-13-20 06:33PM  
10:52AM  
Jul-09-20 02:55PM  
Jul-07-20 10:25AM  
09:52AM  
08:17AM  
07:58AM  
Jul-06-20 01:00PM  
11:33AM  
Jul-04-20 04:07PM  
Jul-02-20 11:00AM  
08:53AM  
08:21AM  
06:04AM  
06:00AM  
Jul-01-20 10:40PM  
10:08PM  
06:35PM  
03:47PM  
10:42AM  
Jun-30-20 11:00AM  
Jun-29-20 04:34PM  
02:10PM  
02:06PM  
07:47AM  
Jun-28-20 11:36PM  
02:23PM  
Jun-26-20 07:32PM  
08:21AM  
07:34AM  
07:23AM  
Jun-25-20 11:30PM  
03:57PM  
03:49PM  
02:49PM  
01:31PM  
05:57AM  
Jun-22-20 02:51PM  
Jun-19-20 06:04PM  
04:32PM  
07:25AM  
Jun-18-20 05:53PM  
Jun-17-20 10:11AM  
09:56AM  
07:30AM  
04:06AM  
Jun-16-20 10:49AM  
Jun-15-20 02:49PM  
Jun-12-20 10:16AM  
Jun-11-20 03:23PM  
11:37AM  
Jun-10-20 01:04PM  
12:58PM  
Jun-09-20 04:28PM  
10:31AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 30Buy17.00125,0002,125,0001,181,258Jul 02 04:16 PM
Novartis Bioventures Ltd10% OwnerNov 12Buy12.00250,0003,000,0003,543,067Nov 12 04:15 PM